Humoral Immunity Emerges as a Spatially Organized, State-Dependent Axis of Antitumor Defense and Therapeutic Targeting

Cancer immunology has historically been framed around cytotoxic T-cell surveillance and the therapeutic release of T-cell checkpoints, but this T-cell-centric view is no longer sufficient to explain the full immune architecture of many tumors. B cells, plasma cells, antibodies, complement, and Fc-receptor-bearing effector cells form a second, highly adaptable arm of antitumor immunity. In several solid tumors, tumor-infiltrating B cells are not passive bystanders: they can present antigen, provide costimulatory signals, shape CD4+ and CD8+ T-cell responses, and differentiate into antibody-secreting plasma cells. Clinical and experimental studies now show that the density, differentiation state, and spatial organization of B-lineage cells can influence prognosis and response to immune checkpoint inhibitors, particularly when B cells are embedded in organized tertiary lymphoid structures (TLS).

These observations have shifted the field from asking whether B cells are present in tumors to asking which B-cell states are present, where they are located, which antigens they recognize, and how their antibodies engage effector or suppressive circuits in the tumor microenvironment (TME). They also force a distinction between beneficial humoral immunity generated locally within structured immune niches and nonproductive antibody deposition or B-cell infiltration that simply accompanies inflammation.

Tertiary Lymphoid Structures as Functional Hubs of Humoral Immunity

TLS are ectopic lymphoid aggregates that arise in chronically inflamed tissues and can reproduce key features of secondary lymphoid organs, including high endothelial venules, follicular dendritic-cell networks, T follicular helper (Tfh) cells, germinal-center-like zones, and local plasma-cell differentiation. In tumors, mature TLS can support antigen-driven B-cell receptor diversification, somatic hypermutation, class-switch recombination, and affinity maturation, thereby generating local IgG- and context-dependent IgA-producing plasma cells.

These TLS-associated reactions can coordinate with T-cell immunity by sustaining antigen presentation and by recruiting Fc-mediated effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation. Mature TLS also provide a spatial scaffold in which CXCL13 (搜索)搜索该靶点, CCL19/CCL21, IL-21, CD40/CD40L, and lymphotoxin signaling can reinforce Tfh-B-cell crosstalk and maintain humoral memory.

The degree of TLS maturation is therefore a functional variable, not only an anatomical descriptor: immature aggregates may recruit lymphocytes without supporting durable germinal-center-like selection, whereas mature TLS can sustain repeated rounds of selection and memory formation. Thus, humoral immunity can amplify a productive tumor-immune cycle rather than merely reflecting the presence of inflammatory infiltrates.

The Double-Edged Nature of Humoral Responses

The same pathways can also be co-opted by tumors. Regulatory B cells that secrete IL-10, TGF-beta, or IL-35; IgA+ plasma-cell programs associated with PD-L1 (搜索)搜索该靶点 and IL-10; IgG4-skewed responses under chronic antigen exposure; inhibitory Fc-gamma receptor signaling; and soluble or chronic immune complexes can dampen cytotoxic immunity and remodel myeloid cells toward tumor-supportive states.

Antibody function therefore depends not only on antigen specificity but also on isotype and subclass, Fc glycosylation, immune-complex geometry, Fc-receptor balance, cytokine milieu, metabolic constraints, and tissue context. A mucosal tumor enriched in IgA-producing cells may require a different interpretation from a non-mucosal tumor dominated by class-switched IgG1/IgG3 plasma cells within mature TLS. Likewise, BCR clonal expansion is informative only when interpreted with somatic hypermutation, class-switching status, phenotype, and spatial localization.

This context dependence explains why indiscriminate B-cell depletion may be harmful in some tumors yet rational in others dominated by diffuse regulatory B-cell infiltrates. It also explains why the same therapeutic class, such as checkpoint blockade or Fc-engineered antibodies, can either amplify protective humoral responses or expose patients to autoimmune toxicity if autoreactive B-cell clones are released from tolerance.

Technological Advances Enable Contextual Interpretation

Technological advances now make this contextual interpretation possible. Bulk B-cell receptor repertoire sequencing can reveal clonal expansion and class switching, but paired single-cell RNA-seq and scBCR-seq connect each clone to a defined transcriptional state, allowing investigators to distinguish germinal-center-like B cells, memory B cells, plasmablasts, plasma cells, and regulatory populations in the same lesion. Spatial transcriptomic and spatial proteomic platforms add the missing anatomical layer by testing whether expanded clones reside inside TLS, at invasive margins, around vessels, or as diffuse infiltrates in immunosuppressive stroma.

Pan-cancer single-cell resources have begun to resolve TIL-B diversity and clinical associations. Fitzsimons and collaborators delineated roughly 10 recurrent B and plasma cell states across cancers, with GC-like B cells and class-switched IgG+ plasma cell states co-varying with TLS signatures and favorable outcome in multiple cohorts. Ma and collaborators combined scRNA-seq with paired BCR-seq to map clonal expansion and somatic hypermutation trajectories within tumors, supporting antigen-driven selection and isotype-specific niches in TLS versus diffuse stroma. Yang and collaborators integrated data from 649 patients across 19 cancer types to map phenotypically distinct B-cell states with therapy-relevant implications.

Importantly, most atlas-derived links between B-cell states and outcome or response are associative; causal claims require orthogonal validation, such as spatial localization or functional perturbation in model systems.

Therapeutic Opportunities and Safety Guardrails

The interplay between humoral immunity and cancer progression suggests numerous points of therapeutic intervention. Broadly, strategies fall into two categories: enhancing beneficial humoral immune responses, and inhibiting or reprogramming harmful humoral elements in biomarker-defined settings.

Direct B-cell-targeting approaches include anti-CD20 (搜索)搜索该靶点 monoclonal antibodies such as rituximab查看药品详情, obinutuzumab查看药品详情, and ofatumumab查看药品详情, which are FDA-approved for B-cell malignancies. Anti-CD19 (搜索)搜索该靶点 CAR T-cell therapies, including tisagenlecleucel查看药品详情, axicabtagene ciloleucel查看药品详情, and lisocabtagene maraleucel查看药品详情, have revolutionized relapsed B-cell acute lymphoblastic leukemia and aggressive lymphomas. In multiple myeloma, BCMA (搜索)搜索该靶点-directed CAR T cells such as idecabtagene vicleucel查看药品详情 and plasma-cell-directed antibodies including daratumumab查看药品详情 (anti-CD38 (搜索)搜索该靶点) and elotuzumab查看药品详情 (anti-SLAMF7查看药品详情) have shown high efficacy. BTK (搜索)搜索该靶点 inhibitors such as ibrutinib查看药品详情, acalabrutinib查看药品详情, and zanubrutinib查看药品详情, along with the PI3Kδ (搜索)搜索该靶点 inhibitor idelalisib查看药品详情, have transformed treatment of B-cell malignancies by disrupting BCR-driven survival signals.

For solid tumors, the trend is more frequently to enhance B cells, especially those forming TLS, because they correlate with good outcomes. Intratumoral administration of a Toll-like receptor 9 (TLR9) agonist (CpG) has been used to spark TLS formation and enhance local B-cell-driven immune activity in melanoma, with encouraging immune activation in early trials. TLS induction approaches leverage CXCL13 (搜索)搜索该靶点/CCL19/CCL21 gradients and LTβR/LIGHT signaling, with STING agonism and biomaterial-based delivery driving intratumoral chemokine and HEV/TLS formation in vivo.

Immune checkpoint inhibitors (ICIs), such as anti-PD-1 (搜索)搜索该靶点/PD-L1 (搜索)搜索该靶点 and anti-CTLA-4 (搜索)搜索该靶点 agents, primarily reinvigorate T cells but also affect B cells and humoral responses. Anti-CTLA-4 can promote formation of TLS and B-cell responses in melanoma, and PD-1 is expressed on B cells, especially in germinal centers. However, checkpoint blockade also has a humoral double-edged effect: by releasing PD-1/PD-L1 or CTLA-4 constraints, ICIs can strengthen Tfh-B-cell crosstalk and tumor-specific antibody responses, yet the same process can expand autoreactive B-cell clones and contribute to immune-related adverse events.

The Case for Neoadjuvant Timing

B-cell expansion and TLS formation are often more interpretable, and potentially more robust, in the neoadjuvant setting because the intact tumor supplies abundant antigen, preserved stromal scaffolds, draining-lymphatic connections, and spatially measurable immune niches. Short-course neoadjuvant therapy also enables paired pretreatment and on-treatment tissue sampling, allowing investigators to detect early CXCL13 (搜索)搜索该靶点 induction, HEV/FDC maturation, Tfh-B-cell proximity, BCR clonal expansion, class switching, and plasma-cell differentiation before surgical removal.

In advanced or heavily pretreated disease, tumor immune editing, necrosis, fibrosis, prior chemotherapy, antibiotics, steroids, and loss of stromal organization may blunt TLS formation or bias B cells toward regulatory programs. This temporal asymmetry should shape clinical trials of B-cell-modulating agents: TLS-inducing or B-cell-enhancing strategies are most rational as window-of-opportunity neoadjuvant studies with mandatory spatial and repertoire endpoints.

Conversely, B-cell depletion, BTK (搜索)搜索该靶点/PI3K inhibition, or IgA/IgG4-axis modulation should not be tested indiscriminately. Pretreatment diagnostic panels should first distinguish TLS-mature tumors, where B-cell depletion may be harmful, from tumors dominated by diffuse IL-10+ Bregs, suppressive IgA+ plasma cells, IgG4 skewing, inhibitory Fc-receptor signaling, or absent TLS, where targeted modulation may be beneficial. These guardrails should be built into eligibility criteria, stratification, and stopping rules.

Toward a Humoral Immune Contexture Classification

The strongest antitumor configuration is emerging as a mature TLS-centered ecosystem: high endothelial venules recruit lymphocytes; follicular dendritic-cell networks and CXCL13 (搜索)搜索该靶点 gradients retain CXCR5+ B cells and Tfh cells; IL-21 and CD40L sustain germinal-center-like selection; and clonally expanded, somatically mutated, class-switched B cells generate plasma cells and memory B cells. In this setting, B cells can present antigen, reinforce CD4+ and CD8+ T-cell activity, and produce IgG1/IgG3-dominant or otherwise productive antibodies that recruit ADCC, ADCP, and complement.

The major limitation for the field is that the same molecules can have opposite consequences depending on anatomical and biochemical context. IgA-rich mucosal tumors may contain cytotoxic antigen-specific IgA immune complexes, but IgA+ regulatory plasma cells in IL-10/TGF-beta-rich niches can suppress CD8+ T cells and bias myeloid FcαRI (搜索)搜索该靶点 signaling toward inhibitory ITAM pathways. IgG4 can mark chronic antigen exposure and may competitively blunt IgG1-mediated Fc effector activity, yet subclass abundance alone does not prove function without antigen specificity, immune-complex geometry, Fc-receptor mapping, and functional readouts.

The final goal is a classification in which each patient is assigned a humoral immune contexture, such as TLS-mature effector, mixed TLS-regulatory, diffuse Breg-dominant, IgA/IgG4-skewed, or humoral-cold, and treated with matching interventions. If these guardrails are implemented, humoral immunity can become a clinically actionable dimension of precision immuno-oncology, complementing T-cell biomarkers while preserving the protective functions of mature TLS.